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Background: The purpose of this study was to examine the postmarketing safety profile of 
aliskiren hemifumarate, a first-in-class direct renin inhibitor.
Methods: The US Adverse Event Reporting System (AERS) was utilized to conduct a 
  retrospective pharmacovigilance analysis by applying the Multi-item Gamma Poisson Shrinker 
data mining algorithm to calculate empiric Bayes geometric mean (EBGM) values of aliskiren-
related adverse event reports. Reports received from January 2007 through December 2008 are 
included in this analysis.
Results: In total, 1592 reports for aliskiren are identified in the AERS. Aliskiren was associ-
ated with reports of angioedema (EBGM 3.9, 95% confidence interval [CI] 3.2–4.7) and renal 
dysfunction (EBGM 3.4, 95% CI 2.6–4.5). Reports of hyperkalemia, dry cough, and diarrhea 
were also linked to aliskiren (EBGM 7.4, 95% CI 3.4–13.0, EBGM 11.0, 95% CI 7.8–14.2, 
EBGM 4.3, 95% CI 3.2–5.8, respectively).
Conclusion: Angioedema and renal dysfunction are potential adverse events associated with 
exposure to aliskiren. Patients with signs and symptoms of angioedema should stop aliskiren 
and seek urgent medical help. Aliskiren should not be used by patients with a risk of renal 
impairment. Additional studies are warranted to quantify further the risk of these events in 
patients with hypertension.
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Introduction
New molecular entities are therapeutic moieties in pharmaceutical dosage forms that 
have not previously been approved for marketing in the US.1 Because of the inherent 
limitations of premarketing clinical (Phase I–III) studies, including the nonrepresen-
tativeness of the study population and the relatively short duration of study follow-up, 
the safety and efficacy of new molecular entities are not thoroughly established prior 
to approval. The process of detection, assessment, and prevention of both potential 
and actual adverse events of pharmaceutical products is termed pharmacovigilance.2 
When this process is implemented during the lifecycle of the product after approval, 
it is termed postmarketing safety surveillance or a Phase IV study, and usually begins 
when the product enters the market.3 While on the market, the utilization and outcomes 
of the product will be exposed to multiple efficacy and safety modifiers that stimulate 
and worsen adverse drug reactions in many ways, including medication errors and 
lack of adherence.
In March 2007, Novartis Pharmaceuticals developed aliskiren hemifumarate as the 
first-in-class direct renin inhibitor indicated for the treatment of hypertension, alone Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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or with other antihypertensive medications. The US Food 
and Drug Administration (FDA) approved the product as a 
new molecular entity under the brand names Tekturna® and 
Tekturna HCT® (a single-pill combination of aliskiren and 
hydrochlorothiazide).4,5 In Europe and Japan, Rasilez® was 
the approved brand name.6 Subsequently, the FDA approved 
  Valturna®, a single-pill combination of aliskiren and   valsartan.7 
Aliskiren is one of the novel agents that modulate the renin-
angiotensin-aldosterone system.
Reports of renal adverse reactions and hyperkalemia 
are documented for drugs affecting the renin-angiotensin-
aldosterone system, including angiotensin-converting 
enzyme inhibitors, angiotensin II receptor antagonists, and 
aldosterone antagonists.8 Rare but serious angioedema and 
other allergic reactions are also recognized for angiotensin-
converting enzyme inhibitors.9,10 By virtue of its mode of 
action, aliskiren modulates the renin-angiotensin-aldosterone 
system, and could have the same renal and metabolic safety 
profiles. Early in 2009, both the European Medicines Agency 
and the Medicines and Healthcare Products Regulatory 
Agency in the United Kingdom alerted health care profes-
sionals and consumers about the increasing risk of acute 
renal failure and serious angioedema as adverse reactions 
of treatment with aliskiren.11–13
Because of the inherent significance of postmarketing 
safety surveillance, the FDA Center for Drug Evaluation 
and Research launched the Adverse Event Reporting System 
(AERS) as a key tool for postmarketing safety surveillance 
of all approved pharmaceutical products. Furthermore, in 
January 2007, the FDA instigated a pilot program to assess 
the value of regular postmarketing safety surveillance for new 
molecular entities.14 As a supplemental source of information 
for the FDA pilot program and health care professionals, 
this retrospective pharmacovigilance study aims to evaluate 
the safety profile of aliskiren hemifumarate by utilizing the 
AERS to assess reports of aliskiren-related adverse drug 
reactions submitted during the period January 2007 through 
December 2008, and implementing the systematic Multi-item 
Gamma Poisson Shrinker (MGPS) methodology to detect the 
magnitude of aliskiren-adverse drug reaction associations in 
the AERS during the study period.
Methods
Data source
The AERS is a voluntary reporting system consisting of 
a database of spontaneous reports of adverse drug events 
maintained by the FDA.15 Reports are received from 
  manufacturers, patients, physicians, pharmacists, and other 
health care professionals throughout the world, with the 
majority of reports being received from within the US. 
AERS is considered a key tool for postmarketing safety 
surveillance of all approved pharmaceutical products. The 
Medical Dictionary for Regulatory Activities (MedDRA) 
Preferred Terms coding scheme is utilized to enter the 
adverse drug reaction reports in the AERS database.16 The 
datasets are published quarterly on the AERS website with 
nonidentifiable information, including demographic details 
about the patient who experienced the adverse drug reac-
tion and the MedDRA Preferred Term that best describes 
the adverse drug reaction, as well as the indication for the 
reported product, the outcome of the event (which describes 
the severity of the adverse drug reaction), information 
about the pharmaceutical product, including product name 
(generic and brand), route, dose, duration of exposure, 
and primary role of the drug in the reported adverse drug 
reaction (primary, secondary, concomitant, or interacting), 
information about the reporter, including occupation and 
country, and type of submitted report   (expedited, periodic, 
or direct).17,18
identifying exposure
Aliskiren was marketed under two brand names, Tekturna 
and Rasilez. In March 2007, Tekturna was approved for the 
treatment of hypertension in the US. In August 2007, Rasilez 
was approved as an antihypertensive in the European Union. 
Two years later, Rasilez was approved for marketing in 
Japan. In January 2008, the FDA approved Tekturna HCT as 
a second-line treatment of hypertension. The same product 
was approved in the European Union one year later. The 
FDA has approved the indication of Tekturna HCT as initial 
treatment for hypertension in patients who need combination 
antihypertensive therapy. In September 2009, Valturna was 
approved by the FDA as a single-pill combination of aliskiren 
and valsartan, an angiotensin II receptor antagonist for the 
treatment of hypertension.6,7
Reports received during the period January 2007 
through December 2008 are included in this study. Reports 
for aliskiren are identified using the keywords “aliskiren”, 
“  Tekturna”, and “Rasilez” in the drug name variable within 
the dataset. Other drugs affecting the renin–angiotensin–
aldosterone system are also identified within the same dataset 
using the verbatim names for each individual class members, 
eg, benazepril hydrochloride (Lotensin®) for angiotensin-
converting enzyme inhibitors, eprosartan mesylate (Teveten®) 
for angiotensin II receptor antagonists, and spironolactone 
(Aldactone®) for aldosterone antagonists.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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identifying adverse drug reactions
Reports for specific adverse drug reactions were identified 
by the MedDRA Preferred Terms utilized in the dataset. 
Clinical judgment was applied to include specific MedDRA 
Preferred Terms for the signs and symptoms of angioedema 
and renal dysfunction.
MgPs data mining algorithm
It is impractical and valueless to quantify the risk of adverse 
drug reactions reported in the AERS utilizing conventional 
analysis methods, because of the inaccurate number of the 
numerator (number of adverse drug reactions), lack of infor-
mation about the denominator (number of patients exposed to 
aliskiren), and background rate of the adverse drug reaction in 
the study population.19 Alternatively, the Multi-item Gamma 
Poisson Shrinker (MGPS) data mining algorithm implements 
empiric Bayesian models to screen for associations between 
the drug and previously unidentified adverse drug reactions.20 
The MGPS calculates empiric Bayes geometric mean (EBGM) 
values, which are the ratios of the observed to the expected 
number of drug-event pairs (reporting ratios). The MGPS 
adjusts for differences in reporting rates by stratifying the 
expected rates by variables in the dataset, eg, demograph-
ics and reporting quarter/year. This adjustment shrinks each 
reporting ratio towards 1. This conservative approach considers 
EBGM values $2.0 to be the safety signal threshold.21 EBGM 
values are reported with their 95% confidence intervals (CI).   
Higher values denote a stronger association between the drug 
and the reported adverse drug reaction.22
Data analysis
AERS datasets were cleaned from duplicated reports, 
merged, and annexed into one major dataset that covers the 
study period; descriptive statistics were performed to exam-
ine adverse drug reaction reporting patterns for aliskiren. 
These steps were performed using SAS software, version 9.2 
of the SAS System for Windows (2010 SAS Institute Inc, 
Cary, NC). The web-based Visual Data Mining Environment 
(WebVDME, 5.0) was applied to conduct the MGPS data 
mining algorithm, and the reporting ratios (EBGM values) 
were estimated with their 95% CI (EB05, EB95).23
Results
Overview of adverse drug  
reaction reports
From January 2007 through December 2008, the AERS 
received 4,178,542 adverse event reports, including 2154 
reports for aliskiren. About 74% (1592) of aliskiren reports 
had valid MedDRA Preferred Terms for adverse events. The 
trend of reporting for aliskiren is presented in Figure 1, which 
indicates an increase in reporting during the last quarter of 
2007, followed by a decline during the subsequent year.
The majority of aliskiren users were elderly females 
(66.1%) of mean age 68 years (95% CI 66–70), in whom 
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Table 1 Description of adverse event reports for aliskiren in the 
Us Adverse event Reporting system for 2007–2008
Characteristics n (%)*
Patient age (years)
  20–44 17 (5.6)
  45–64 98 (32.1)
  65–84 162 (53.1)
  85–100 28 (9.2)
Patient gender
  Female 692 (66.1)
  Male 355 (33.9)
Report types
  expedited 328 (27.4)
  Periodic 854 (71.2)
  Direct 17 (1.4)
  serious 131 (28.4)
Reporter profession
  Physician 429 (37.6)
  Pharmacist 29 (2.5)
  Other health care provider 49 (4.3)
  Consumer 633 (55.5)
  Lawyer 1 (0.1)
Reporter country
  United states 1082 (90.9)
  Overseas 108 (9.1)
Note: *Percentage of reports within characteristic category.
Table 2 Distribution of adverse event reports for aliskiren by 
organ system class in the Us Adverse event Reporting system 
for 2007–2008
Body system Adverse event MedDRA term n
Body as a whole Asthenia 27
Alopecia 22
Fatigue 21
Feeling abnormal 10
Cardiovascular hypertension 74
Blood pressure 69
inadequately controlled
hypotension 38
Cerebrovascular accident 13
hypertensive crisis 10
Blood pressure fluctuation 10
gastrointestinal Diarrhea 49
Abdominal pain 34
nausea 17
Dyspepsia 17
increased hepatic enzyme 13
Central nervous Dizziness 61
headache 24
Anxiety 13
Depression 11
Respiratory Cough 44
Dyspnea 15
Metabolic hyponatremia 17
hyperkalemia 16
Urogenital Acute renal failure 29
increased blood creatinine 29
Musculoskeletal Arthralgia 17
Myalgia 15
Pain in extremity 10
skin Angioedema 36
Peripheral edema 28
Rash 25
Lip swelling 11
Pruritus 10
Other Drug ineffective 44
Abbreviation: MedDRA, Medical Dictionary for Regulatory Activities.
the predominant indication of aliskiren was hyperten-
sion (95.6% of reports). The vast majority of the reports 
were received from within the US (91%), exclusively 
for   Tekturna, while Rasilez-related reports were received 
from   overseas,   specifically the European Union, Canada, 
and South   America. Consumers, including patients and 
their caregivers, represented the main reporting entities for 
aliskiren-related reports, where 56% of reports were directly 
submitted by consumers. Among health care profession-
als, physicians and pharmacists reported 38% and 3% of 
the direct reports, respectively. Other health care profes-
sionals, including nurses, submitted 4.3% of the adverse drug 
reaction reports. Most of the reports that were submitted by 
the manufacturer to the FDA were periodic, ie, received 
quarterly (72.2%). Expedited reports that are received within 
15 days of an adverse drug reaction represented about 
28% of the manufacturer-submitted reports. Expedited 
reports include unlabeled and serious events. Aliskiren was 
administered orally in tablet form with a dosing range of 
75–600 mg, and an aliskiren/hydrochlorothiazide dosing 
range of 150/12.5–300/25 mg per day. Among reports with 
valid dosage information, about 43% consisted of patients 
exposed to a 150 mg daily dose of aliskiren, compared with 
about 17% of exposures to the 300 mg daily dose. Table 1 
describes the reports for aliskiren received during the study 
period. Adverse effects with a reporting frequency of $10 
reports during the study period are listed by organ system 
class in Table 2.
Angioedema
Angioedema is a rare allergic reaction to angiotensin-  converting 
enzyme inhibitors and angiotensin II receptor antagonists 
that causes swelling of the face, throat, and sometimes the 
extremities. Laryngeal angioedema is a serious adverse drug 
reaction because it causes suffocation and death. During the 
analysis period, aliskiren was associated with 36 reports of 
angioedema. Reports for the signs and symptoms of angioe-
dema were: peripheral edema (n = 28), dyspnea (15), lip swell-
ing (11), dysphagia (7), joint swelling (7), face swelling (6),   Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Table 3 Distribution of serious adverse event reports for aliskiren 
in the Us Adverse event Reporting system for 2007–2008
Severity category Adverse event MedDRA term n (%)*
Death Unknown event 6 (37.5)
Cerebrovascular accident 2 (12.5)
Pulmonary edema 2 (12.5)
Cyanosis 2 (12.5)
Convulsion 2 (12.5)
Angioedema 2 (12.5)
Life-threatening Arrhythmia 3 (23.0)
increased alanine aminotransferase 2 (15.4)
Loss of consciousness 2 (15.4)
Angioedema 2 (15.4)
Atrial fibrillation 2 (15.4)
Malaise 2 (15.4)
hospitalization Angioedema 12 (18.0)
Arrhythmia 5 (7.5)
Asthenia 4 (6.0)
Fluctuation in blood pressure 4 (6.0)
edema 4 (6.0)
increased blood creatinine 3 (4.5)
Acute renal failure 3 (4.5)
Abdominal pain 3 (4.5)
Chest pain 3 (4.5)
hypertension 3 (4.5)
Abdominal discomfort 3 (4.5)
Cardiac failure 2 (3.0)
Diarrhea 2 (3.0)
Drug ineffective 2 (3.0)
gastrointestinal hemorrhage 2 (3.0)
hypertensive crisis 2 (3.0)
Pulmonary hypertension 2 (3.0)
neutropenia 2 (3.0)
stevens–Johnson syndrome 2 (3.0)
increased alanine aminotransferase 2 (3.0)
Cerebrovascular accident 2 (3.0)
Disability Dysuria 2 (100)
Note: *Percentage of reports within severity category. 
Abbreviation: MedDRA, Medical Dictionary for Regulatory Activities.
pharyngeal edema (5), eyelid edema (5), throat tightness (4), 
exertional dyspnea (2), mouth edema (2),   swollen tongue (2), 
periorbital edema (1), and laryngospasm (1). The total number 
of identified reports for potential aliskiren-linked angioedema 
is 132 (8.3% of total reports). The majority of reported cases 
for angioedema (81%) was associated with a daily aliskiren 
dose of 150 mg. Two reports of death, two reports of life-
threatening events, and 12 reports of hospitalization were 
attributed to angioedema.
Renal dysfunction
Reports of aliskiren-linked renal dysfunction were identified 
as: acute renal failure (n = 29), increased blood creatinine (29), 
pollakiuria (8), proteinuria (6), dysuria (6), increased blood 
urea (4), nocturia (2), decreased glomerular filtration rate (1), 
renal impairment (1), renal disorder (1), renal artery stenosis 
(1), renal pain (1), dialysis (1), azotemia (1), chromaturia (1), 
hematuria (1), polyuria (1), and decreased urine output (1). 
The total number of reports for potential aliskiren-related renal 
dysfunction events was 95 (6.0% of total reports). Most of the 
reports were linked to an aliskiren daily dose of 150 mg. Three 
reports of acute renal failure and three for increased blood 
creatinine were linked to hospitalization, and two reports of 
dysuria were associated with disability.
serious adverse drug reaction reports
Serious adverse drug reactions are events that occur at any dose 
resulting in death, a life-threatening episode, initial and prolon-
gation of hospitalization, disability, or congenital anomaly.24 
A total of 130 reports were considered serious, ie, death   
(n = 18), life-threatening events (18), requiring hospitaliza-
tions (92), resulting in disability (2), and one report requiring 
an intervention. Reports of serious events related to aliskiren 
with a reporting frequency of at least two reports during the 
study period are described in Table 3. About 38% of deaths 
were reported for unknown adverse reactions, 23% of life-
threatening adverse event reports were related to arrhythmia, 
and 18% of inpatient hospitalization reports were linked to 
angioedema.
Other adverse reactions
Other aliskiren-related adverse events at a frequency of $15 
reports in the AERS included hypotension, hyperkalemia, 
hyponatremia, dyspepsia, diarrhea, abdominal pain, nausea, 
cough, rash, headache, dizziness, fatigue, asthenia, alopecia, 
arthralgia, and myalgia. The role of aliskiren in all adverse 
drug reaction reports was 93% primary, 5% secondary, and 
2% concomitant with other drugs.
Data mining results
Compared with other renin–angiotensin–aldosterone system 
modulators, aliskiren was associated with the highest report-
ing ratio for angioedema (EBGM 3.9, 95% CI 3.2–4.7), renal 
dysfunction (EBGM 3.4, 95% CI 2.6–4.5), diarrhea (EBGM 
4.3, 95% CI 4.2–13.0), and dry cough (EBGM 11.0, 95% CI 
7.8–14.2). Among the groups, aliskiren ranked the second 
after aldosterone antagonists for hyperkalemia reporting 
rates (EBGM 7.4, 95% CI 4.2–13.0) Figure 2 presents the 
reporting ratios of selected adverse events for aliskiren and 
other renin–angiotensin–aldosterone system modulators. 
Analyzing the individual MedDRA terms for angioedema 
yielded essentially similar EBGM values to the combined 
MedDRA terms for signs and symptoms of angioedema, 
with no significant effect on study conclusions.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Figure 2 Empiric Bayes geometric mean values and 95% confidence intervals (EB05, EB95) of selected adverse events for renin–angiotensin–aldosterone system modulators 
in the Us Adverse event Reporting system for 2007–2008.
Discussion
The FDA AERS database was utilized to conduct this ret-
rospective pharmacovigilance study for evaluation of the 
postmarketing safety profile of aliskiren hemifumarate, 
the first-in-class direct renin inhibitor among the 18 new 
molecular entities approved by the FDA in 2007.25 Reports of 
adverse reactions to aliskiren (Tekturna, Rasilez) during the 
period January 2007 through December 2008 were included 
in the analysis. Aliskiren was associated with a large number 
of reports of angioedema, renal dysfunction, hyperkalemia, 
gastrointestinal disorders, and cough. The findings with 
regard to angioedema and renal dysfunction are consistent 
with the clinical trials and safety reports received by the 
European Medicines Agency.13,26–28
It is important to point out that the specificity of adverse events 
reported in the AERS is not thoroughly established, therefore 
a causal association between aliskiren, angioedema, and renal 
impairment cannot be certain. Other coexisting medical con-
ditions and/or comedications could confound the   association. 
Angiotensin-converting enzyme inhibitors have long been in 
the market and shown to promote angioedema through a surfeit 
of bradykinin production; similarly, aliskiren does not break-
down bradykinin, which could account for the side effects 
of dry cough and angioedema.9,29 The higher EBGM values 
for angioedema and renal dysfunction are consistent with 
clinical studies, and thus are unlikely to be due to detection 
bias.26–28
One of the advantages of data mining in the AERS is to pro-
vide early indicators of adverse reactions for marketed phar-
maceutical products.19,30 Premarketing clinical studies usually 
investigate the drug in specific small samples of patients for 
short durations. Rare, unlabeled, and serious adverse events 
may not become evident until the drug enters the market, 
when a larger number of diverse patients are exposed to the   
drug in different clinical settings. The capability to esti-
mate EBGM values (reporting ratios) for every drug-event 
combination in the database is a strength of the data mining 
approach, which aids in comparing reporting ratios for a 
specific adverse drug reaction across different drugs. It is 
important not to interpret such ratios as relative risks or 
incidence rates. Data mining allows efficient comparisons 
of drug-event combinations in a large database (clinical 
trials for such combinations are resource-intensive and time-
consuming). Data mining also enables detection of safety 
signals for drug-event combinations that might go undetected 
in a massive database because of the vast number of drugs Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
343
Adverse events with aliskiren
and events involved and the intricacy of the database. It is 
surprising to find a decline in adverse event reporting for such   
a novel chemical (Figure 1); this reduction could correspond 
to a reduction in utilization for multiple reasons, including 
the novelty of the product, unavailability of updated hyper-
tension treatment guidelines with regard to aliskiren, or the 
occurrence of side effects. Experiencing adverse reactions 
discourages prescribers from increasing the dosage, which 
could partially explain the finding that the majority of reports 
were associated with aliskiren in daily doses of 150 mg.
Furthermore, higher EBGM values reflect a stronger 
association between the drug and the events. It does not 
provide evidence of causality between the drug and the event. 
EBGM points to the relative frequency of angioedema and 
reports of renal dysfunction for aliskiren, compared with all 
drugs and adverse event reports in the AERS database dur-
ing the study period. Likewise, lower EBGM values do not 
provide evidence of tolerability. Detection bias, reporting 
bias, and confounding by indication cannot be discounted in 
AERS analysis. EBGM values can be increased or decreased 
depending upon the length of time the drug has been on the 
market and the AERS delay in utilization of MedDRA Pre-
ferred Terms codes in the database.19 However, the period of 
analysis for aliskiren reports was brief and the FDA applied a 
consistent revised version of MedDRA Preferred Terms codes 
in adverse event documentation during the study period. For 
a variety of reasons, underreporting of adverse events in the 
AERS is the major limitation of the database. Therefore, it 
is likely that the actual number of cases of angioedema and 
renal failure in the AERS are underestimated.30
Development and continuation of postmarketing safety 
surveillance for new molecular entities is important for estab-
lishing the safety and effectiveness of new molecular entities. 
Three criteria are suggested by the FDA pilot program in 
order to consider a new molecular entity for postmarketing 
safety surveillance, ie, the length of time the product has been 
on the market, the number of adverse event reports in the 
AERS database, and the clinical indication for which the new 
molecular entity is prescribed.14 In addition to these factors, 
the inclusion and exclusion criteria for the study sample in 
premarketing studies for the new molecular entity should be 
considered as well. For example, the safety of aliskiren with 
regard to angioedema in African American patients was not 
studied prior to marketing.26
Conclusion
Treatment with aliskiren hemifumarate (Tekturna, Rasilez) 
may be associated with angioedema and renal failure. This 
study shows higher than expected reports of angioedema 
and renal impairment for aliskiren. Consistent with recom-
mendations from the European Medicines Agency,13 the FDA 
should alert health care professionals about the possibility 
of encountering angioedema and renal impairment with use 
of aliskiren. This could be accomplished by a product label 
change and sending letters to health care professionals warn-
ing about cautious administration of aliskiren in patients at 
risk of acute renal failure, including those with renal artery 
stenosis or other risks for renal dysfunction, eg, hypovolemia, 
and cardiac or hepatic disease. Moreover, the precaution sec-
tion of the product leaflet should clearly state that patients 
with signs and symptoms of angioedema after using aliskiren 
should cease aliskiren therapy and seek prompt medical 
help, and the contraindication section should mention that 
aliskiren must not be administered to patients who have 
previously experienced angioedema after using aliskiren. In 
addition, concomitant use of aliskiren with drugs that worsen 
renal function and disturb plasma potassium levels should 
be avoided, in particular, nonsteroidal anti-inflammatory 
drugs, where both efficacy and renal tolerability of aliskiren 
are compromised by concomitant administration.13 Further-
more, aliskiren-related signs of angioedema, renal failure, 
and hyperkalemia should be listed on the potential safety 
signals page of the FDA AERS website, and it is recom-
mended to create a similar listing within the new molecular 
entity approval history webpage of the FDA.25,31
Given the voluntary nature of the AERS, the results of 
the current hypothesis-screening study should not be causally 
interpreted as epidemiologic comparison treatment groups.32 
Robust observational epidemiologic studies, including lon-
gitudinal designs, are recommended to establish causality 
and risk factors for adverse reactions, eg, race. Furthermore, 
longer durations of postmarketing data are needed to quantify 
the risks further and examine the safety signals of aliskiren 
in patients with hypertension.
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